Clinical Trial Update: Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluated dupilumab with topical corticosteroids in children 6 to less than 12 years with severe atopic dermatitis; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Dupilumab (dupilumab)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Dermatitis, Atopic | Phase 3 | Status: COMPLETED | Results posted: 2020-08-13